CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
|CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Patent applications|
|Patent application number||Title||Published|
|20130281427||CRYSTALLINE FORM OF ERTAPENEM SODIUM AND PREPARATION METHOD THEREFOR - Provided is a crystalline form E of ertapenem sodium. Further provided is a method for preparing a crystalline form E of ertapenem sodium, characterized by using an aqueous ertapenem sodium solution at a low concentration as a raw material. The crystalline form E can be easily filtered and dried, the properties in the drying process are stable, and the purity of the crystal is high and can be up to 98.5% or higher.||10-24-2013|
|20130089549||B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF - The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.||04-11-2013|
|20120095209||INTERMEDIATE OF ERTAPENEM, A COMPOSITION COMPRISING THE SAME AND PREPARATION METHODS THEREOF - Intermediates of Ertapenem of formula 2a wherein Np represents (I) or (II), and P||04-19-2012|
|20110118263||BENZOTHIOPHENE ALKANOL PIPERAZINE DERIVATIVES AND THEIR USE AS ANTIDEPRESSANT - The invention discloses benzothiophene alkanol piperazine derivatives and their use as antidepressants. The invention discloses the said benzothiophene alkanol piperazine derivative having triple inhibition effect on the reuptake of 5-HT, NA and DA. Compared with clinical used antidepressants so far having single target, e.g. desipramine and fluoxetine, and clinical used antidepressants so far having double targets, e.g venlafaxine and duloxetine, the said benzothiophene alkanol piperazine derivatives of the present invention may have a broader indication range and less toxic and side effects to nervous system. The benzothiophene alkanol piperazine derivatives are the compounds with the following formula or their pharmaceutically acceptable salts, wherein Ar||05-19-2011|
Patent applications by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.